{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T12:48:52Z","timestamp":1793882932842,"version":"4.7.0"},"reference-count":24,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,9,10]],"date-time":"2024-09-10T00:00:00Z","timestamp":1725926400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Catastrophic antiphospholipid syndrome (CAPS) is a life-threatening condition of small-vessel thrombosis with acute multiple-organ involvement and visceral damage. In this report, we present a case of a patient with CAPS who is refractory to conventional therapy. For the first time in a patient with CAPS, marked C5b-9 formation was demonstrated on microvascular endothelial cells, suggesting the usefulness of therapeutic complement inhibition in this setting. Eculizumab, a C5-blocking monoclonal antibody, is remarkably effective in the treatment of different forms of thrombotic microangiopathy by controlling complement system hyperactivation. It halted the \u201cthrombotic storm\u201d and promptly achieved full recovery of thrombocytopenia. However, kidney function did not recover, possibly because eculizumab was administered too late. Conceivably, the timing of treatment is crucial to achieving disease remission before irreversible structural damage occurs in target organs, thereby preventing their complete functional recovery.<\/jats:p>","DOI":"10.3389\/fimmu.2024.1460317","type":"journal-article","created":{"date-parts":[[2024,9,10]],"date-time":"2024-09-10T04:39:56Z","timestamp":1725943196000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":11,"title":["Case report: Timing of eculizumab treatment in catastrophic antiphospholipid syndrome"],"prefix":"10.3389","volume":"15","author":[{"given":"Camillo","family":"Carrara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Blerina","family":"Mataj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Gastoldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piero","family":"Ruggenenti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Savino","family":"Sciascia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dario","family":"Roccatello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,9,10]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)60709-X","article-title":"Antiphospholipid syndrome","volume":"376","author":"Ruiz-Irastorza","year":"2010","journal-title":"Lancet"},{"key":"B2","doi-asserted-by":"publisher","first-page":"17103","DOI":"10.1038\/nrdp.2017.103","article-title":"Antiphospholipid syndrome","volume":"4","author":"Schreiber","year":"2018","journal-title":"Nat Rev Dis Primers"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2017.124","article-title":"Diagnosing antiphospholipid syndrome: \u201cextra-criteria\u201d manifestations and technical advances","volume":"13","author":"Sciascia","year":"2017","journal-title":"Nat Rev Rheumatol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-204838","article-title":"Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: a multicentre prospective study of 1000 patients","volume":"74","author":"Cervera","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1191\/0961203303lu394oa","article-title":"Catastrophic antiphospholipid syndrome: international consensus statement on classification criteria and treatment guidelines","volume":"12","author":"Asherson","year":"2003","journal-title":"Lupus"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2016.07.020","article-title":"Complement and thrombosis in the antiphospholipid syndrome","volume":"15","author":"Oku","year":"2016","journal-title":"Autoimmun Rev"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019003863","article-title":"Complement activity and complement regulatory gene mutations are associated with thrombosis in APS and CAPS","volume":"135","author":"Chaturvedi","year":"2020","journal-title":"Blood"},{"key":"B8","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMc0809959","article-title":"Eculizumab for congenital atypical hemolytic-uremic syndrome","volume":"360","author":"Gruppo","year":"2009","journal-title":"N Engl J Med"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1038\/nrneph.2012.195","article-title":"STEC-HUS, atypical HUS and TTP are all diseases of complement activation","volume":"8","author":"Noris","year":"2012","journal-title":"Nat Rev Nephrol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1308826","article-title":"Eculizumab in atypical hemolytic\u2013uremic syndrome","volume":"369","author":"Legendre","year":"2013","journal-title":"N Engl J Med"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc0910965","article-title":"Eculizumab and renal transplantation in a patient with CAPS","volume":"362","author":"Lonze","year":"2010","journal-title":"N Engl J Med"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2022.103055","article-title":"Eculizumab use in catastrophic antiphospholipid syndrome (CAPS): Descriptive analysis from the \u201cCAPS Registry","volume":"21","author":"L\u00f3pez-Benjume","year":"2022","journal-title":"Autoimmun Rev"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-02-558296","article-title":"Dynamics of complement activation in aHUS and how to monitor eculizumab therapy","volume":"124","author":"Noris","year":"2014","journal-title":"Blood"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00449","article-title":"Complement in the pathophysiology of the antiphospholipid syndrome","volume":"10","author":"Chaturvedi","year":"2019","journal-title":"Front Immunol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"e143","DOI":"10.1097\/MD.0000000000000143","article-title":"Efficacy of eculizumab in a patient with immunoadsorption-dependent catastrophic antiphospholipid syndrome: a case report","volume":"93","author":"Kronbichler","year":"2014","journal-title":"Medicine"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2014\/704371","article-title":"36-year-old female with catastrophic antiphospholipid syndrome treated with eculizumab: a case report and review of literature","volume":"2014","author":"Strakhan","year":"2014","journal-title":"Case Rep Hematol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1097\/RHU.0000000000000290","article-title":"Eculizumab induces sustained remission in a patient with refractory primary catastrophic antiphospholipid syndrome","volume":"21","author":"Zikos","year":"2015","journal-title":"JCR: J Clin Rheumatol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kew040","article-title":"Complement activation is a crucial pathogenic factor in catastrophic antiphospholipid syndrome","volume":"55","author":"Barratt-Due","year":"2016","journal-title":"Rheumatology"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/key228","article-title":"Eculizumab for catastrophic antiphospholipid syndrome\u2014a case report and literature review","volume":"57","author":"Guillot","year":"2018","journal-title":"Rheumatology"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2019.03.015","article-title":"Evidence of complement activation in the thrombotic small vessels of a patient with catastrophic antiphospholipid syndrome treated with eculizumab","volume":"18","author":"Ruffatti","year":"2019","journal-title":"Autoimmun Rev"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1177\/0961203320917460","article-title":"Thrombotic microangiopathy in the course of catastrophic antiphospholipid syndrome successfully treated with eculizumab: case report and systematic review of the literature","volume":"29","author":"Skoczynska","year":"2020","journal-title":"Lupus"},{"key":"B22","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.semarthrit.2018.11.005","article-title":"Secondary thrombotic microangiopathy in systemic lupus erythematosus and antiphospholipid syndrome, the role of complement and use of eculizumab: Case series and review of literature","volume":"49","author":"Kello","year":"2019","journal-title":"Semin Arthritis Rheumatism"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020007499","article-title":"Patients with refractory catastrophic antiphospholipid syndrome respond inconsistently to eculizumab","volume":"136","author":"Yelnik","year":"2020","journal-title":"Blood"},{"key":"B24","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1053\/ajkd.2000.8994","article-title":"Waterhouse-Friderichsen syndrome and bilateral renal cortical necrosis in meningococcal sepsis","volume":"36","author":"Agraharkar","year":"2000","journal-title":"Am J Kidney Dis"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1460317\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,10]],"date-time":"2024-09-10T04:39:59Z","timestamp":1725943199000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1460317\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,10]]},"references-count":24,"alternative-id":["10.3389\/fimmu.2024.1460317"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2024.1460317","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,10]]},"article-number":"1460317"}}